ArticleScientific reports2025
Lactate-related lncRNAs assessment model predicts the prognosis of pancreatic ductal adenocarcinoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Lactate-induced epithelial-mesenchymal transition: a metabolic nexus in pancreatic cancer metastasis.Translational cancer research · 2026Review
- Epigenetic modulation to overcome immune suppression in pancreatic cancer.Clinical epigenetics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Accumulative lactate acid is a critical feature of pancreatic ductal adenocarcinoma (PDAC). Increasing evidence has demonstrated a close correlation between long non-coding RNAs (lncRNAs) and the survival of patients with PDAC. Nevertheless, research on the prognostic value of lactate-related lncRNAs in PDAC remains limited. In this study, the lactate-related lncRNAs were characterized based on their association with hypoxia-related genes in TCGA and StarBase database. Specifically, the dysregulated lactate-related lncRNAs in PDAC were identified as LA-DElncRNAs. Four LA-DElncRNAs were selected to develop clinical model, which demonstrated strong performance in survival prediction. The risk score derived from the model was identified as an independent prognostic factor for PDAC. Importantly, patients in the low-risk groups displayed more favorable prognoses compared to those in the high-risk groups. Moreover, patients with different risk scores showed distinct immune subtypes and variations in the levels of immune checkpoints. FAM225B was the most significant LA-DElncRNA associated with prognosis in Cox analysis, and the biological role of FAM225B was investigated both in vitro and in vivo. Knockdown of FAM225B, a significant LA-DElncRNAs, attenuated the proliferation and invasion of PDAC cells. In conclusion, the assessment model based on LA-DElncRNAs holds promise as a potential prognostic biomarker of PDAC patients. The identified four LA-DElncRNAs could help unravel the mechanisms underlying pancreatic tumorigenesis and identify novel molecular targets for treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.